Case reportPublished 2015
Fishing for Precision in ALK-Rearranged Non-Small-Cell Lung Cancers
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) represent the current standard for identification of therapeutically relevant anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers (NSCLCs). Use of tyrosine kinase inhibitors (TKIs) targeting the oncogenic ALK fusion protein is approved for use in advanced ALK-rearranged NSCLCs and with benefits both with regards to clinical outcomes and quality of life when compared with traditional palliative cytotoxic therapies. We report here 2 cases in which initial standard of care ALK testing by FISH yielded false positive results, leading to delays in determination of optimal systemic therapy.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalOncology & Cancer Case Reports
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Xiuning Le”
- BylineArticles whose byline prints “Mary Linton Peters”
- BylineArticles whose byline prints “Paul A VanderLaan”
- BylineArticles whose byline prints “Daniel B Costa”
- BylineArticles whose byline prints “Deepa Rangachari”